诊断性穿刺标本中B7-H3表达与转移性前列腺癌生存相关
研究评估135例转移性前列腺癌和113例局限性前列腺癌患者诊断性穿刺标本中肿瘤B7-H3表达水平,发现转移性癌中高表达更常见(31% vs 12%,p=0.0003)。在转移性癌中,高B7-H3表达独立与更高的疾病特异性死亡率(多因素HR=2.72,p=0.047)和总死亡率(多因素HR=2.04,p=0.025)相关。
要点
- 转移性前列腺癌穿刺标本中B7-H3高表达比例显著高于局限性癌(31% vs 12%)。
- 转移性癌中高B7-H3表达独立预测疾病特异性死亡(HR=2.72)和总死亡(HR=2.04)。
- B7-H3或可辅助筛选侵袭性转移性前列腺癌并指导靶向治疗分层。
核心结论
- 诊断性穿刺标本中肿瘤B7-H3高表达是转移性前列腺癌不良生存的独立相关因素。
研究设计与样本
- 回顾性评估135例转移性前列腺癌和113例局限性前列腺癌患者诊断性穿刺标本的肿瘤B7-H3表达水平。
主要发现
- 转移性癌中高B7-H3表达更常见(31% vs 12%,p=0.0003)。
- 局限性癌中B7-H3表达状态与生化复发无进展生存无关。
- 转移性癌中高B7-H3表达独立相关于更高的疾病特异性死亡率(多因素HR=2.72,p=0.047)。
- 转移性癌中高B7-H3表达独立相关于更高的总死亡率(多因素HR=2.04,p=0.025)。
临床怎么用
- 对转移性前列腺癌患者,可考虑检测穿刺标本B7-H3表达以辅助风险分层。
- 高B7-H3表达的转移性前列腺癌患者可能更适合B7-H3靶向免疫治疗临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer. METHODS: We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer. RESULTS: High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%; p = 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72; p = 0.047) and overall mortality rates (multivariable HR = 2.04; p = 0.025). CONCLUSIONS: Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.
引用
- Amori G, Sugawara E, Shigematsu Y, et al. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33558663. doi:10.1038/s41391-021-00331-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。